Entering text into the input field will update the search result below

China-U.S. IPO Pipeline Creaks Back To Life With 2 New Listing Plans

Nov. 01, 2021 12:31 PM ETAtour Lifestyle Holdings Limited (ATAT), LIAN
Bamboo Works profile picture
Bamboo Works


  • Two Chinese companies, drug maker LianBio and hotel operator Atour, are moving ahead with U.S. IPOs after a three-month pause on such listings.
  • Neither company is using the controversial VIE structure, and neither comes from the sensitive internet sector.
  • One place where we can expect big changes is in the “risk” section of Chinese companies going forward.

IPO letter in the billboard screen

jxfzsy/iStock via Getty Images

Drug maker LianBio and hotel operator Atour each aims to raise about $350 million with separate New York listings

A year ago, the imminent IPO by Chinese company LianBio (NASDAQ:LIAN) wouldn’t have drawn much

This article was written by

Bamboo Works profile picture
Got a great investment idea on a US- or Hong Kong-listed China stock but don't know how to spread the word? We can help! Contact us at investors@thebambooworks.com. Bamboo Works (www.thebambooworks.com) is the premium source for news and analysis on Chinese companies listed in the United States and Hong Kong, with a strong focus on mid-cap and also pre-IPO companies. Contact us at info@thebambooworks.com to learn about opportunities for sponsored content.

Recommended For You


Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.